Abstract
Invasive pneumococcal disease (IPD) has an all-cause mortality of 5–35 % in the developed world. Pneumococcal vaccination is recommended for at-risk groups, including those infected with human immunodeficiency virus (HIV) and those over 65 years of age. However, adherence to vaccination guidelines is low. We reviewed all cases of IPD in our tertiary referral hospital from 2006 to 2010. IPD was defined as the isolation of Streptococcus pneumoniae from a normally sterile site with a compatible clinical syndrome. Demographics, risk factors, susceptibilities, pneumococcal serotype, mortality, and vaccination status for each patient were analyzed. There were 127 IPD episodes in 122 patients. The overall case fatality rate was 21.2 %. Seventy-two percent of the patients had two or more risk factors that should have prompted pneumococcal vaccination. However, the overall pneumococcal vaccination provision was only 9 %: 64.6 % of all typed isolates were contained in the pneumococcal polysaccharides vaccine 23 (PPV23), 48.8 % in the 7-valent pneumococcal conjugate vaccine (PCV7), and 60.1 % in PCV13. All isolates were fully sensitive to penicillin and cefotaxime. Recurrent IPD was seen in 11 % of the HIV-infected patients, highlighting a particular at-risk group. IPD has a high mortality rate. There is low vaccine provision in our study, although most IPD patients had risk factors that should have prompted vaccination. HIV-positive people are particularly at risk; vaccinating those with persisting CD4 counts less than 200 cells/mm3 and the use of “prime-boost” strategies may decrease incidence in the future. Newer models of care such as a dedicated vaccine clinic as described in this study may help increase vaccine provision and uptake.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shariatzadeh MR, Huang JQ, Tyrrell GJ et al (2005) Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine (Baltimore) 84(3):147–161
Kalin M, Örtqvist Å, Almela M et al (2000) Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 182:840–847. doi:10.1086/315760
Stanek RJ, Mufson MA (1999) A 20-year epidemiological study of pneumococcal meningitis. Clin Infect Dis 28:1265–1272
Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (2010) Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 59(34):1102–6
Noakes K, Pebody RG, Gungabissoon U et al (2006) Pneumococcal polysaccharide vaccine uptake in England, 1989–2003, prior to the introduction of a vaccination programme for older adults. J Public Health (Oxf) 28(3):242–7, Epub 2006 Jul 4
Sintes X, Nebot M, Izquierdo C et al; Working Group for the Study of Prevention of CAP in the Elderly (2011) Factors associated with pneumococcal and influenza vaccination in hospitalized people aged ≥65 years. Epidemiol Infect 139(5):666–73, Epub 2010 Aug 9
Hoshi SL, Kondo M, Okubo I (2010) Pricing and uptake rate of public funded pneumococcal vaccination for the elderly in Japan. Nihon Koshu Eisei Zasshi 57(7):505–513
Al-Sukhni W, Avarino P, McArthur MA et al (2008) Impact of public vaccination programs on adult vaccination rates: two examples from Ontario, Canada. Vaccine 26(11):1432–1437
Centers for Disease Control and Prevention (CDC) Self-reported pneumococcal vaccination coverage trends 1989–2008 among adults by age group, risk group, race/ethnicity, health-careworker status, and pregnancy status, United States, National Health Interview Survey (NHIS). Available online at: http://www.cdc.gov/flu/pdf/professionals/nhis89_08ppvvaxtrendtab.pdf
Mereckiene J, O’Donnell J, Collins C et al (2007) Risk groups and uptake of influenza and pneumococcal vaccine in Ireland. Euro Surveill 12(12):E13–E14
Conway R, Galvin S, Coveney S et al (2013) Deprivation as an outcome determinant in emergency medical admissions. QJM 106(3):245–251
Tuite H. Personal communication: PACHI-1 (unpublished data)
Clinical and Laboratory Standards Institute (CLSI) (2008) Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. CLSI, Wayne, PA
Immunisation Guidelines for Ireland, 2008 Edition (with updated corrections and amendments, August 2010). National Immunisation Advisory Committee (NIAC) of the Royal College of Physicians of Ireland
U.S. Department of Health and Human Services. Healthy People 2020. Available online at: http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=23. Accessed 25th February 2013
Health Protection Surveillance Centre (HPSC) Epidemiological data. Available online at: http://www.hpsc.ie/hpsc/A-Z/VaccinePreventable/PneumococcalDisease/EpidemiologicalData/. Accessed 3rd January 2013
Kaye P, Malkani R, Martin S et al (2009) Invasive pneumococcal disease (IPD) in England and Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines. Presented at the 27th annual meeting of the European Society for Pediatric Infectious Diseases (ESPID 2009), Brussels, Belgium, June 2009. Available online at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581527892. Accessed 25th February 2013
Jackson LA, Janoff EN (2008) Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 47(10):1328–38
Joint Committee on Vaccination and Immunisation (JCVI) (2011) JCVI statement on the routine pneumococcal vaccination programme for adults aged 65 years and older. 20 July 2011. Available online at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_128704.pdf. Accessed 25th February 2013
Bliss SJ, O’Brien KL, Janoff EN et al (2008) The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 8:67–80
Feikin DR, Feldman C, Schuchat A et al (2004) Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 4:445–455
AM Geretti on behalf of the BHIVA Immunization Writing Committee (2008) British HIV Association guidelines for immunization of HIV-infected adults 2008. Available online at: http://www.bhiva.org/documents/Guidelines/Immunisation/Immunization2008.pdf. Last accessed 25th February 2013
Turett GS, Blum S, Telzak EE (2001) Recurrent pneumococcal bacteremia: risk factors and outcomes. Arch Intern Med 161:2141–2144
Nuorti JP, Butler JC, Gelling L et al (2000) Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 132:182–190
French N, Gordon SB, Mwalukomo T et al (2010) A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362(9):812–822
Lesprit P, Pédrono G, Molina JM et al; ANRS 114-Pneumovac Study Group (2007) Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 21(18):2425–2434
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Rock, C., Sadlier, C., Fitzgerald, J. et al. Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center. Eur J Clin Microbiol Infect Dis 32, 1135–1141 (2013). https://doi.org/10.1007/s10096-013-1859-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-013-1859-z